AK137 (Bispecific Antibody Targeting CD73 and LAG-3) in Patients With Advanced Malignant Tumors
NCT06691360 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87
Last updated 2024-11-15
Summary
A Phase I open label, dose-escalation and expansion study to evaluate the safety, tolerability, pharmacokinetics and antitumor activity of AK137 in patients with advanced malignant tumors.
Conditions
- Advanced Malignant Tumors
Interventions
- DRUG
-
AK137
IV infusion, specified dose on specified days.
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-12-31
- Primary Completion
- 2027-05-31
- Completion
- 2027-08-31
Countries
- China
Study Locations
More Related Trials
-
A Study of AK112 in Advanced Malignant Tumors
NCT05214482 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
A Phase Ia/Ib Open Label，Clinical Study Evaluating the Safety, Tolerability and Preliminary Efficacy of AK127 in Combination With AK104 in Patients With Advanced Malignant Tumors
NCT05868876 ·Status: RECRUITING ·Phase: PHASE1
-
A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors
NCT05229497 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
AK129 Combination Therapy for Advanced Solid Tumors
NCT06943820 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Phase Ib/II Study of AK104 and AK117 in Combination With or Without Chemotherapy in Advanced Malignant Tumors
NCT05235542 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Anti-PD-1 and VEGF Bispecific Antibody AK112 in Combination With Chemotherapy in Patients With ES-SCLC
NCT05116007 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy
NCT07010263 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of Anti-PD-1 and LAG-3 Bispecific Antibody(AK129) Combined With Chemotherapy With or Without Cadonilimab in the First-line Treatment of Unresectable Locally Advanced or Metastatic G/ GEJ Adenocarcinoma
NCT06586294 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of GNC-077 in Patients With Locally Advanced or Metastatic Non-small-cell Lung Cancer and Other Solid Tumors
NCT06612840 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer
NCT03501056 ·Status: WITHDRAWN ·Phase: PHASE2
-
A Study of AK104 in Subjects With Locally Advanced Unresectable or Metastatic MSI-H/dMMR Solid Tumors
NCT04547101 ·Status: TERMINATED ·Phase: PHASE2
-
Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors
NCT05689853 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer
NCT06519669 ·Status: TERMINATED ·Phase: NA
-
A Phase 1/2 Study of 7MW3711 in Advanced Solid Tumors
NCT06008366 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of a PD-1/CTLA-4 Bispecific Antibody AK104 in Patients With Metastatic Nasopharyngeal Carcinoma
NCT04220307 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of AK-1286 in Patients With Advanced Solid Tumors
NCT06779045 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of IMM2510 + IMM27M Combination Therapy in Patients With Advanced Solid Tumors
NCT06764836 ·Status: RECRUITING ·Phase: PHASE1
-
CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors
NCT06939270 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
First-In-Human Study of Bispecific Antibody MR001 In Subjects With Advanced Solid Tumors
NCT06134531 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study of IMM2510 + IMM01 Combination Therapy in Patients With Advanced Solid Tumors
NCT07170787 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors
NCT07208773 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
IMM2520, a PD-L1 and CD47 Bispecific Antibody in Patients With Advanced Solid Tumors
NCT05780307 ·Status: RECRUITING ·Phase: PHASE1
-
Study of Activated CIK Armed With Bispecific Antibody for Advanced Liver Cancer
NCT03146637 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Liver Cancer
NCT03484962 ·Status: WITHDRAWN ·Phase: PHASE2
-
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
NCT06031597 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3